SCHEMBL23052274

SCHEMBL23052274

CC(C)C(C)NC(=O)c1cnc(-c2cccc(-c3cc(C(=O)NC(C4CC4)C4CC4)n(CC(O)C(F)(F)F)n3)c2)o1

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 2/20 0.34
▸ KCNK3 O14649 1/20 0.32
▸ MET P08581 1/20 0.32
▸ USP30 Q70CQ3 1/20 0.32
▸ PHGDH O43175 2/20 0.31
▸ TRPV4 Q9HBA0 1/20 0.31
▸ MMEL1 Q495T6 1/20 0.31
▸ CHRM2 P08172 2/20 0.31
▸ MMP13 P45452 2/20 0.31
▸ CHRM1 P11229 1/20 0.31
▸ SCN10A Q9Y5Y9 1/20 0.31
▸ ALPL P05186 1/20 0.31
▸ CYP1A2 P05177 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ GRIN1 Q05586 1/20 0.30
▸ GRIN2B Q13224 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23041555 0.93 MME (0.35) MMEKCNK3METUSP30PHGDH
SCHEMBL29452454 0.93 MME (0.35) MMEKCNK3METUSP30PHGDH
SCHEMBL23041557 0.93 MME (0.35) MMEKCNK3METUSP30PHGDH
SCHEMBL23041436 0.92 MME (0.36) MMEUSP30PHGDHTRPV4MMEL1
SCHEMBL23041433 0.92 MME (0.36) MMEUSP30PHGDHTRPV4MMEL1
SCHEMBL23041682 0.91 POLB (0.35) MMEKCNK3MMP13SCN10ACYP1A2
SCHEMBL23041680 0.91 POLB (0.35) MMEKCNK3MMP13SCN10ACYP1A2
SCHEMBL29452809 0.91 POLB (0.35) MMEKCNK3MMP13SCN10ACYP1A2
SCHEMBL23041684 0.91 POLB (0.35) MMEKCNK3MMP13SCN10ACYP1A2
SCHEMBL23041473 0.90 HTT (0.36) MMEKCNK3METUSP30PHGDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021038426-A1 SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-03-04 — — WO disclosed
Send feedback